Literature DB >> 22786901

Presence and physiologic function of the renin-angiotensin system in mouse lacrimal gland.

Saori Yaguchi1, Yoko Ogawa, Shigeto Shimmura, Shin Hatou, Shigeru Nakamura, Takaaki Inaba, Toshihiro Imada, Yoko Ozawa, Yutaka Kawakami, Susumu Ishida, Kazuo Tsubota.   

Abstract

PURPOSE: To investigate the expression, localization, and physiologic function of renin-angiotensin system (RAS) components in the mouse lacrimal gland.
METHODS: Lacrimal glands and cultured lacrimal gland fibroblasts from wild-type (WT) BALB/c (H-2(d)) mice were used. Reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry were used to determine the expression and localization of the RAS components, prorenin/renin, angiotensin-converting enzyme (ACE), angiotensin II, angiotensin II type 1 receptor (AT1R), and angiotensin II type 2 receptor (AT2R) in the normal mouse lacrimal gland. To examine the change in tear secretion, mice received ARB (AT1R blocker) or AT2R antagonist. Tear secretion was assessed by cotton thread test before and after drug administration.
RESULTS: The mRNAs coding for angiotensinogen, prorenin, ACE, and both AT1R and AT2R were found in normal lacrimal gland tissue and cultured lacrimal gland fibroblasts. Prorenin/renin and ACE were identified in myoepithelial cells around ducts and acini and in blood vessels. Angiotensin II, AT1R, and AT2R were observed in the ducts and interstitial fibroblasts. AT1R and AT2R were also localized in blood vessels. All the cultured lacrimal gland fibroblasts expressed angiotensin II, AT1R, and AT2R. Tear secretion increased in mice that received ARB.
CONCLUSIONS: The results are consistent with the hypothesis that a tissue-specific RAS is present in the lacrimal gland, and suggest that fibroblasts are one of the cell types playing a role in the tissue RAS. Tissue RAS might be involved in tissue function of regulating tear secretion in the lacrimal gland.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22786901     DOI: 10.1167/iovs.12-9891

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  6 in total

1.  Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid.

Authors:  Shin Mukai; Yoko Ogawa; Fumihiko Urano; Chie Kudo-Saito; Yutaka Kawakami; Kazuo Tsubota
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

2.  Losartan and isoproterenol promote alterations in the local renin-angiotensin system of rat salivary glands.

Authors:  Isadora Prado Cano; Thiago José Dionisio; Tânia Mary Cestari; Adriana Maria Calvo; Bella Luna Colombini-Ishikiriama; Flávio Augusto Cardoso Faria; Walter Luiz Siqueira; Carlos Ferreira Santos
Journal:  PLoS One       Date:  2019-05-22       Impact factor: 3.240

Review 3.  SARS-COV-2 and Ocular Surface: From Physiology to Pathology, a Route to Understand Transmission and Disease.

Authors:  Dalton de Freitas Santoro; Luciene Barbosa de Sousa; Niels O S Câmara; Denise de Freitas; Lauro Augusto de Oliveira
Journal:  Front Physiol       Date:  2021-02-12       Impact factor: 4.566

Review 4.  Autoimmune Epithelitis and Chronic Inflammation in Sjögren's Syndrome-Related Dry Eye Disease.

Authors:  Yoko Ogawa; Tsutomu Takeuchi; Kazuo Tsubota
Journal:  Int J Mol Sci       Date:  2021-10-30       Impact factor: 5.923

5.  Angiotensin II type 1 receptor antagonist attenuates lacrimal gland, lung, and liver fibrosis in a murine model of chronic graft-versus-host disease.

Authors:  Saori Yaguchi; Yoko Ogawa; Shigeto Shimmura; Tetsuya Kawakita; Shin Hatou; Shingo Satofuka; Shigeru Nakamura; Toshihiro Imada; Hideyuki Miyashita; Satoru Yoshida; Tomonori Yaguchi; Yoko Ozawa; Takehiko Mori; Shinichiro Okamoto; Yutaka Kawakami; Susumu Ishida; Kazuo Tsubota
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

Review 6.  A glimpse at the aging eye.

Authors:  Jonathan B Lin; Kazuo Tsubota; Rajendra S Apte
Journal:  NPJ Aging Mech Dis       Date:  2016-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.